Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Oct;13(10):1088-1097.
doi: 10.1002/cpdd.1454. Epub 2024 Sep 13.

A Phase 1, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Bepirovirsen in Adults with Hepatic Impairment and Healthy Participants (B-Assured)

Nadia Noormohamed  1 , Tamara Lukic  2 , Thomas C Marbury  3 , Eric J Lawitz  4 , Holly Prescott  5 , Mindy Magee  1 , Ahmed Nader  1 , Kelong Han  1
Affiliations
Clinical Trial

A Phase 1, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Bepirovirsen in Adults with Hepatic Impairment and Healthy Participants (B-Assured)

Nadia Noormohamed et al. Clin Pharmacol Drug Dev. 2024 Oct.

Abstract

Bepirovirsen is a developmental antisense oligonucleotide (ASO) for treatment of chronic hepatitis B virus infection. No pharmacokinetic (PK) studies comparing participants with hepatic impairment (HI) and healthy participants (HPs) have been conducted with ASOs. Given the target patient population, characterization of bepirovirsen PK in HI was imperative. This phase 1, nonrandomized, open-label study (NCT04971928) evaluated the PKs of a single 300-mg dose of bepirovirsen in participants with HI and matched HPs, enrolled in 2 parts (Part 1: moderate HI; Part 2: mild HI). If no predefined difference in the area under the concentration-time curve from time 0 (predose) to infinite time (AUC0-∞) and maximum observed concentration (Cmax; geometric mean ratio [GMR] 0.5-1.5) was identified in Part 1, findings were applied to mild HI, eliminating Part 2. Participants were monitored for 50 days post-treatment and noncompartmental analysis estimated PK parameters. Twenty-four participants (moderate HI, n = 12; HP, n = 12) received bepirovirsen and completed Part 1. AUC0-∞ and Cmax were lower in participants with moderate HI (GMR 0.69 and 0.67, respectively) than in HPs, while apparent clearance (CL/F) and apparent terminal phase volume of distribution (Vz/F) were higher (GMR 1.44 and 1.64, respectively), but fell within the predefined thresholds of difference for this study. Part 2 was omitted. Adverse events were mild. Moderate HI did not have a clinically relevant impact on bepirovirsen PK or safety.

Keywords: antisense oligonucleotide; bepirovirsen; hepatic impairment; hepatitis B; pharmacokinetics.

PubMed Disclaimer

References

    1. Polaris Observatory Collaborators. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet Gastroenterol Hepatol. 2023;8(10):879‐907.
    1. Mak L‐Y, Cruz‐Ramón V, Chinchilla‐López P, et al. Global epidemiology, prevention, and management of hepatocellular carcinoma. Am Soc Clin Oncol Educ Book. 2018;(38):262‐279.
    1. Vittal A, Ghany MG. WHO guidelines for prevention, care and treatment of individuals infected with HBV: a US perspective. Clin Liver Dis. 2019;23(3):417‐432.
    1. Cornberg M, Lok AS, Terrault NA, Zoulim F, Faculty E‐AHTEC. Guidance for design and endpoints of clinical trials in chronic hepatitis B ‐ report from the 2019 EASL‐AASLD HBV Treatment Endpoints Conference (double dagger). J Hepatol. 2020;72(3):539‐557.
    1. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370‐398.

Publication types

Substances

LinkOut - more resources